

ABBOTT INDIA LIMITED**DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE PERIOD APRIL 1, 2018 TO MARCH 31, 2019****A) Parties where control exists :**

Ultimate Holding Company : Abbott Laboratories, USA

Holding Company : Abbott Capital India Ltd., UK

B) Other related parties with whom transactions have taken place during the year :**I) Fellow subsidiaries :**

British Colloids Ltd., U.K.

Abbott Healthcare Products Ltd., U.K

Abbott Healthcare Private Ltd., India

Abbott International LLC, USA

Abbott Products Operations AG, Switzerland

Abbott Laboratories (Singapore) Pte Ltd., Singapore

Abbott Manufacturing Pte Ltd., Singapore

Abbott GmbH & Co. K.G., Germany

Alere Medical Private Limited, India

Abbott Laboratories S.A., Switzerland

Abbott Laboratories S.A., Dubai

II) Key management personnel :

Mr. Ambati Venu, Managing Director

Mr. Rajiv Sonalker, Whole-time Director (w.e.f. August 8, 2017)

Mr. Munir Shaikh, Chairman

Mr. Rajendra Shah, Independent Director (ceased to be the Director effective as on March 31, 2019)

Mr. Ranjan Kapur, Independent Director (ceased to be the Director effective January 27, 2018 due to demise)

Mr. Krishna Mohan Sahni, Independent Director

Ms. Anisha Motwani, Independent Director (w.e.f. April 25, 2018)

C) Transactions during the year :**I) Transactions with the holding company during the year**

(Rupees in Lakhs)

	For the year ended March 31, 2019	For the year ended March 31, 2018
Abbott Capital India Ltd., UK		
Remittance of dividend	58,95.50	42,87.64

II) Transactions with fellow subsidiaries during the year**i) Remittance of dividend :**

	For the year ended March 31, 2019	For the year ended March 31, 2018
British Colloids Ltd., U.K.		
Remittance of dividend	8,08.50	5,88.00
Abbott Healthcare Products Ltd., U.K		
Remittance of dividend	20,59.72	14,97.98

ii) Sales to fellow subsidiaries :

	For the year ended March 31, 2019	For the year ended March 31, 2018
Abbott Healthcare Private Ltd., India		
Sales of stock-in-trade	56,24.56	53,65.79
Sales of raw materials	46,79.97	54,94.81
Sales of capital goods	32.99	-

iii) Purchases from fellow subsidiaries :

	For the year ended March 31, 2019	For the year ended March 31, 2018
Abbott Healthcare Private Ltd., India		
Purchases of raw materials	4,93.78	4,57.99
Purchases of stock-in-trade	120,73.92	138,76.53
Abbott Products Operations AG, Switzerland		
Purchases of raw materials	296,21.37	185,78.10
Purchases of stock-in-trade	35,46.38	39,34.76

iv) Purchase of trademarks/capital goods from ultimate holding company and fellow subsidiaries :

	For the year ended March 31, 2019	For the year ended March 31, 2018
Abbott Laboratories, USA		
Purchase of trademarks	-	2,83.14
Abbott GmbH & Co. K.G., Germany		
Purchase of trademarks	-	4,27.65
Alere Medical Private Limited, India		
Purchases of capital goods	12.09	-



ABBOTT INDIA LIMITED
DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE PERIOD APRIL 1, 2018 TO MARCH 31, 2019
v) Other expenses to fellow subsidiaries:

	(Rupees in Lakhs)	
	For the year ended March 31, 2019	For the year ended March 31, 2018
Abbott Healthcare Private Ltd., India		
Promotional Expenses	1,54.74	1,84.84
Conversion charges	9,15.63	2,39.65
Alere Medical Private Limited, India		
Promotional Expenses	2.22	-

vi) Loan/deposit and interest to/from fellow subsidiaries :

	For the year ended March 31, 2019	For the year ended March 31, 2018
Abbott Healthcare Private Ltd., India		
Interest free security deposit paid	-	14,79.87
Interest free security deposit received	-	44.66
Alere Medical Private Limited, India		
Loan given	-	200,00.00
Interest income on above loan	12,54.80	5,20.55

vii) Reimbursements to and from fellow subsidiaries :

	Reimbursement to		Reimbursement from	
	For the year ended March 31, 2019	For the year ended March 31, 2018	For the year ended March 31, 2019	For the year ended March 31, 2018
Abbott Healthcare Private Ltd., India				
Shared and support services	10,14.00	10,52.03	-	-
Rent expenses	33,60.60	32,93.22	-	-
Market research and other expenses	-	-	13.15	16.42
Excise duty payment/cenvat recovery on Loan Licensee manufacturing	-	38.10	-	1,78.89
Abbott International LLC, USA				
Employee benefits expense, travel and other expenses	34.04	36.98	-	-
Abbott Manufacturing Pte Ltd., Singapore				
Employee benefits expense, travel and other expenses	-	-	8.47	22.45
Abbott Laboratories (Singapore) Pte Ltd., Singapore				
Employee benefits expense, travel and other expenses	12.52	24.62	19.01	-
Abbott Products Operations AG., Switzerland				
Employee benefits expense, travel and other expenses	-	-	1,20.35	1,77.80
Abbott Laboratories S.A., Switzerland				
Employee benefits expense, travel and other expenses	-	-	6.30	-

viii) Income from fellow subsidiaries :

	For the year ended March 31, 2019	For the year ended March 31, 2018
Abbott Healthcare Private Ltd., India		
Shared and support services	16,26.00	16,27.73
Rent income	1,14.53	28.63
Abbott Products Operations AG., Switzerland		
Shared and support services	5,08.51	5,26.33
Abbott Laboratories S.A., Dubai		
Shared and support services	33.60	-
Abbott Laboratories (Singapore) Pte Ltd., Singapore		
Shared and support services	33.60	-

ix) Key management personnel remuneration* :

	For the year ended March 31, 2019	For the year ended March 31, 2018
Mr. Ambati Venu, Managing Director	6,50.75	5,85.89
Mr. Rajiv Sonalker - Whole-time Director (w.e.f. August 8, 2017)	3,04.76	1,61.64

* During the year, as a part of the 'Long Term Incentive Program', Restricted Stock Units of Abbott Laboratories, USA carrying perquisite value of Rs.2,69.88 Lakhs (March 31, 2018 : Rs.1,23.72 Lakhs) have been granted to the above employees.

Also, provision for post employment benefits as contribution to gratuity fund, leave encashment on retirement and other defined benefits which are made based on actuarial valuation on an overall Company basis are not included in remuneration to key management personnel.



ABBOTT INDIA LIMITED**DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE PERIOD APRIL 1, 2018 TO MARCH 31, 2019**

x) Non-Executive, Other Directors' sitting fees :

(Rupees in Lakhs)

	For the year ended March 31, 2019	For the year ended March 31, 2018
Mr. Munir Shaikh, Chairman	15.00	13.50
Mr. Rajendra Shah, Independent Director (ceased to be the Director effective as on March 31, 2019)	16.00	17.00
Mr. Ranjan Kapur, Independent Director (ceased to be the Director effective January 27, 2018 due to demise)	-	10.50
Mr. Krishna Mohan Sahn, Independent Director	14.50	15.00
Ms. Anisha Motwani, Independent Director (w.e.f. April 25, 2018)	13.00	-

D) Outstanding :

	As at March 31, 2019	As at March 31, 2018
Trade payables to fellow subsidiaries		
Abbott Products Operations AG., Switzerland	109,66.44	56,34.60
Abbott Healthcare Private Ltd., India	18,05.45	16,73.23
Alere Medical Private Limited, India	3.88	-
	127,75.77	73,07.83
Other payables to fellow subsidiaries		
Abbott Healthcare Private Ltd., India	44.66	44.66
	44.66	44.66
Trade receivables from fellow subsidiaries		
Abbott Healthcare Private Ltd., India	54,45.04	22,72.66
	54,45.04	22,72.66
Other receivables from fellow subsidiaries		
Abbott Products Operations AG., Switzerland	47.68	90.39
Abbott Healthcare Private Ltd., India	1,17.97	35.92
Alere Medical Private Limited, India	-	4,68.49
Abbott International LLC, USA	3,98.31	-
Abbott Laboratories S.A., Switzerland	6.13	-
Abbott Laboratories S.A., Dubai	32.99	-
Abbott Laboratories (Singapore) Pte, Singapore	10.86	-
	6,13.94	5,94.80
Loan and deposit to fellow subsidiaries		
Abbott Healthcare Private Ltd., India	14,67.67	14,69.86
Alere Medical Private Limited, India #	-	200,00.00

The above loan is guaranteed by Abbott Laboratories, USA i.e. the ultimate holding company.

Terms and conditions of transactions with related parties :

All transactions with related parties are made in the ordinary course of business and the same is at arm's length. Outstanding balances at the year end are unsecured and settlement occurs in cash. The Company has not recorded any impairment for receivables. This assessment is undertaken each financial year through examining the financial position of the related parties and the market in which related parties operate.

